Effectiveness of GLP‐1RA according to different type 2 diabetes phenotypes: A retrospective study
Abstract Aims Type 2 diabetes (T2D) is a heterogeneous disease, with varying pathogenetic mechanisms influencing treatment response. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) offer clear metabolic benefits in T2D, but interindividual variability in response is observed.
Irene Caruso+9 more
wiley +1 more source
An Unusual Case of Membranoproliferative Glomerulonephritis: Is the Role of Vaccination in Immune Reactivation a Casual or Causal Effect? [PDF]
Rodríguez Tudero C+4 more
europepmc +1 more source
Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study. [PDF]
Cong G, Qin Y, Wang X, Sui M.
europepmc +1 more source
Recombinant growth hormone for children with systemic lupus erythematosus and linear growth delay: A report of two cases and literature review. [PDF]
Liu F+8 more
europepmc +1 more source
Associations Between Renal Dysfunction Subtypes and Vertebral Fracture in Patients with Type 2 Diabetes: A Longitudinal Study. [PDF]
Hu N+5 more
europepmc +1 more source
How does LAMB2 contribute to kidney disease? Insights from a pediatric case. [PDF]
Trutin I+4 more
europepmc +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
David Ranzinger+4 more
wiley +1 more source
PLA2R1 and HLA-DQA1 SNP in patients with primary membranous nephropathy. [PDF]
Zhou J+12 more
europepmc +1 more source
Type I IFN receptor blockade by anifrolumab reduces cutaneous lupus in monogenic SLE
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Julian Steininger+3 more
wiley +1 more source